Rajesh Chopra joins board of e-Therapeutics

Dr Rajesh Chopra is to join the board of e-Therapeutics as a non-executive director.

He serves as VP of translational and early drug development at Celgene and joins UK-based drug discovery and development company e-Therapeutics as it prepares to advance several investigational drugs into clinical trials.

Prior to his current role at Celgene, where he is leading efforts to integrate drug discovery and clinical development at Celgene sites in the US and Europe, Chopra spent five years at AstraZeneca (AZ).

During his time at AZ he eventually held the role of medical science director, senior principal scientist and disease area team leader for blood cancers.

Chopra has also held positions outside pharma, working as a clinician and academic in the UK, and spent seven years as clinical director of the Department of Haematological Oncology at the Christie Hospital in Manchester. He is also a a Fellow of both the Royal College of Physicians and the Royal College of Pathologists in the UK.

Professor Oliver James, chair of e-Therapeutics, said: “Rajesh's appointment represents a further significant strengthening of our Board. He brings highly relevant senior-level experience gained in world-leading pharma and biotech companies and substantial expertise in oncology.

“His input will be of great value as we advance our clinical programmes and bring more new drugs through into development from our discovery operation.”